Stock Research for IBB

Featured Broker: Ally Invest

Get the due diligence for another stock.


IBB Stock Chart & Research Data

The IBB chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IBB chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


IBB Due diligence Resources & Stock Charts

The IBB stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IBB Detailed Price Forecast - CNN Money CNN View IBB Detailed Summary - Google Finance
Yahoo View IBB Detailed Summary - Yahoo! Finance Zacks View IBB Stock Research & Analysis -

Stock Analysis

TradeIdeas View IBB Trends & Analysis - Trade-Ideas Barrons View IBB Major Holders - Barrons
NASDAQ View IBB Call Transcripts - NASDAQ Seeking View IBB Breaking News & Analysis - Seeking Alpha
Spotlight View IBB Annual Report - OTC Report View IBB OTC Short Report -
TradeKing View IBB Fundamentals - TradeKing Charts View IBB SEC Filings - Bar Chart
WSJ View Historical Prices for IBB - The WSJ Morningstar View Performance/Total Return for IBB - Morningstar
MarketWatch View the Analyst Estimates for IBB - MarketWatch CNBC View the Earnings History for IBB - CNBC
StockMarketWatch View the IBB Earnings - StockMarketWatch MacroAxis View IBB Buy or Sell Recommendations - MacroAxis
Bullish View the IBB Bullish Patterns - American Bulls Short Pains View IBB Short Pain Metrics -

Social Media Mentions

StockTwits View IBB Stock Mentions - StockTwits PennyStocks View IBB Stock Mentions - PennyStockTweets
Twitter View IBB Stock Mentions - Twitter Invest Hub View IBB Investment Forum News - Investor Hub
Yahoo View IBB Stock Mentions - Yahoo! Message Board Seeking Alpha View IBB Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for IBB - Insider Cow View Insider Transactions for IBB - Insider Cow
CNBC View IBB Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IBB - OTC Markets
Yahoo View Insider Transactions for IBB - Yahoo! Finance NASDAQ View Institutional Holdings for IBB - NASDAQ

Stock Charts

FinViz View IBB Stock Insight & Charts - StockCharts View IBB Investment Charts -
BarChart View IBB Stock Overview & Charts - BarChart Trading View View IBB User Generated Charts - Trading View

Latest Financial News for IBB

Why Sarepta Therapeutics Stock Is Starting to Shine Again
Posted on Friday January 11, 2019

Sarepta Therapeutics (NASDAQ:SRPT) started 2019 with very high volatility. After spiking to around $125 a share on Jan. 7, SRPT stock gave up those gains when markets took in the developments in its DMD pipelines and its Exondys 51 fourth-quarter sales outlook. Although shares rebounded from December 2018 lows, should biotech stock investors seriously consider investing in this company? At the J.P. Morgan conference, Sarepta said it will run 45 biopsies this quarter for SRP-4045. This is an investigational compound that treats DMD or Duchenne muscular dystrophy patients with mutations in the DMD gene. The drug works by directing cells, through Sarepta's PMO, to skip exon 45 when processing RNA. The dystrophin protein is shortened but is still synthesized, slowing the negative symptoms of DMD. If the biopsies are positive, Sarepta will file a marketing application, setting up a possible approval date of early 2020. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### SRPT's Sales Outlook SRPT stock volatility rose after the company issued its revenue outlook for Exondys 51. In the fourth quarter ended Dec. 31, 2018, it made $84.4 million in revenue from sales of Exondys 51. For 2018, revenue was around $301 million. It ended that same period with a healthy balance of $1.1 billion in cash. * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors Markets reacted negatively to the outlook because it expected quarterly revenue of $85.8 million. The barely $2 million difference is a rounding error and the market quickly realized it. Quarterly revenue is in line with forecasts. As markets rebounded, taking the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) up 11.5% on the week, SRPT stock also rose the same amount (11%). Sarepta's global growth plans should lower the risks of relying solely in one market: "We continue to build our international presence with limited infrastructure but dedicated colleagues in Latin America and Europe and a managed access program or MAP now live in some 44 countries. We should continue to see modest contribution from our MAP throughout 2018 with increasing contribution in 2019 and beyond." Source: SA Transcript ### Impressive Talent at Sarepta Sarepta highlighted the 25 programs in RNA and gene therapy underway. Its staff talent consists of over 500 professionals. This leading gene therapy team could deliver on bringing 3 RNA-therapies by 2020. It may potentially treat 30% of the DMD market. Historically, the team is showing that it is delivering. FY 2018 revenue nearly doubled to $301 million, up from the 2017 revenue of $154.6 million. ### Investing Opportunity Sarepta is a top five rare disease company by market cap. Only Alexion Pharmaceuticals (NASDAQ:ALXN), BioMarin Pharmaceutical (NASDAQ:BMRN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are bigger. SRPT stock is underperforming compared to its peers. While the other firms' stock price traded closer to its 52-week highs after the market rally in the last few days, Sarepta is still around 33% below its yearly high. Wall Street coverage gained steam in the last few days. The company received over five "buy" calls, with a price target ranging from $161 to as high as $267. Analyst Firm Position Price Target Date Debjit Chattopadhyay H.C. Wainwright Buy $267.00 yesterday Salveen Richter Goldman Sachs Buy $191.00 2 days ago Matthew Harrison Morgan Stanley Buy $161.00 2 days ago Brian Skorney Robert W. Baird Buy $202.00 2 days ago Alethia Young Cantor Fitzgerald Buy $217.00 2 days ago Yun Zhong Janney Montgomery Buy $200.00 2 days ago Brian Abrahams RBC Capital Buy -- 3 days ago Martin Auster Credit Suisse Buy $189.00 3 days ago Tim Chiang BTIG Buy $190.00 13 days ago Source: tipranks ### Investment Suitability Like with all biotech companies in the discovery phase, SRPT is volatile and risky. Any FDA approval delays could disappoint markets, sending the stock lower. Clinical study costs could rise, but in Sarepta's case, the company has plenty of cash on hand. It is unlikely to need a cash raise through a share sale. * 7 Stocks to Buy That Are Run By Billionaires ### Bottom Line on SRPT Stock Sarepta Therapeutics stock benefited from the latest rebound in biotechnology stocks, but could move even higher in the longer term. It has a goal of commencing its confirmatory trial with commercial material this year. Given the strong team, doctors and scientists involved, chances are good that the trial, which has 24 patients, goes well and will bring positive results. As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post Why Sarepta Therapeutics Stock Is Starting to Shine Again appeared first on InvestorPlace.

Bear market in value stocks is ending, Wells Fargo predicts a 2019 comeback
Posted on Friday January 11, 2019

Wells Fargo's Christopher Harvey expects value names to be the big winners in the second half of 2019.

Two ways to play the biotech boom
Posted on Tuesday January 08, 2019

Biotech stocks are on fire after a string of deals in the space. Here are two ways investors could play the space.

Biotech's breaking out, and here's why some market experts think an even bigger rally is ahead
Posted on Tuesday January 08, 2019

Biotech just saw a big rally, and market experts believe the sector could have more room to run.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.